ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.71
-0.78%
US Tech 100
21,524.40
0.41%
S&P 500
6,114.63
-0.01%
US Dollar vs CAD
1.41918
0.02%
Bitcoin
96,111.57
-0.02%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Vir Biotechnology Inc (VIR) Share Price

Vir Biotechnology Inc

Vir Biotechnology Inc (VIR)

Vidrala SA
9.65
0.07
(0.73%)
Closed February 17 3:00PM
Delayed by 15 minutes
9.79
0.14
(1.45%)
After Hours: 5:57PM
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
9.79
Bid
9.57
Ask
10.08
Volume
862,834
9.58 Day's Range 10.01
6.56 52 Week Range 14.43
Market Cap
1.348B
Previous Close
9.58
Open
9.58
Last Trade
100
@
9.79
(formt)
Last Trade Time
Financial Volume
US$ 8,391,427
VWAP
9.7254
Average Volume (3m)
2,193,767
Shares Outstanding
137,720,120
Dividend Yield
-
PE Ratio
-2.16
Earnings Per Share (EPS)
-4.47
Revenue
86.18M
Net Profit
-615.06M

About Vir Biotechnology Inc

Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, an... Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.vir.bio
Headquarters
Wilmington, Delaware, USA
Founded
-
Vir Biotechnology Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker VIR. The last closing price for Vir Biotechnology was US$9.58. Over the last year, Vir Biotechnology shares have traded in a share price range of US$ 6.56 to US$ 14.43.

Vir Biotechnology currently has 137,720,120 shares outstanding. The market capitalization of Vir Biotechnology is US$1.32 billion. Vir Biotechnology has a price to earnings ratio (PE ratio) of -2.16.

Ask ADVFN Intelligence (AI)

VIR Latest News

More News

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 14 2025
VIR (0.73%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
February 13 2025
VIR (0.73%)

Form 8-K - Current report
Edgar (US Regulatory)
January 30 2025
VIR (0.73%)

Form 8-K - Current report
Edgar (US Regulatory)
January 08 2025
VIR (0.73%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
December 04 2024
VIR (0.73%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
December 02 2024
VIR (0.73%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.43-4.2074363992210.2210.658.8412787019.3611402CS
4-0.37-3.6417322834610.1611.268.84133112210.07292227CS
122.7939.8571428571714.436.93219376710.2779267CS
261.2614.77139507628.5314.436.5614940929.48848109CS
520.697.582417582429.114.436.5612819599.66675323CS
156-22.29-69.482543640932.0833.116.56120427416.25377712CS
260-7.32-42.781998831117.11141.016.56122114827.21815618CS

VIR - Frequently Asked Questions (FAQ)

What is the current Vir Biotechnology share price?
The current share price of Vir Biotechnology is US$ 9.79
How many Vir Biotechnology shares are in issue?
Vir Biotechnology has 137,720,120 shares in issue
What is the market cap of Vir Biotechnology?
The market capitalisation of Vir Biotechnology is USD 1.32B
What is the 1 year trading range for Vir Biotechnology share price?
Vir Biotechnology has traded in the range of US$ 6.56 to US$ 14.43 during the past year
What is the PE ratio of Vir Biotechnology?
The price to earnings ratio of Vir Biotechnology is -2.16
What is the cash to sales ratio of Vir Biotechnology?
The cash to sales ratio of Vir Biotechnology is 15.44
What is the reporting currency for Vir Biotechnology?
Vir Biotechnology reports financial results in USD
What is the latest annual turnover for Vir Biotechnology?
The latest annual turnover of Vir Biotechnology is USD 86.18M
What is the latest annual profit for Vir Biotechnology?
The latest annual profit of Vir Biotechnology is USD -615.06M
What is the registered address of Vir Biotechnology?
The registered address for Vir Biotechnology is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Vir Biotechnology website address?
The website address for Vir Biotechnology is www.vir.bio
Which industry sector does Vir Biotechnology operate in?
Vir Biotechnology operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
JTAIJet AI Inc
US$ 6.02
(133.33%)
104.48M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
254.39M
WRDWeRide Inc
US$ 31.4877
(83.39%)
21.07M
INLFINLIF Limited
US$ 16.27
(80.58%)
7.68M
MBRXMoleculin Biotech Inc
US$ 2.1201
(66.94%)
136.66M
BLACBellevue Life Sciences Acquisition Corporation
US$ 3.08
(-56.31%)
425.19k
BLACUBellevue Life Sciences Acquisition Corporation
US$ 3.36
(-52.68%)
5.21k
CSAICloudastructure Inc
US$ 19.0001
(-49.58%)
1.01M
NEXNNexxen International Ltd
US$ 10.30
(-49.16%)
160.99k
BSLKBolt Projects Holdings Inc
US$ 0.6626
(-46.13%)
13.07M
CNSPCNS Pharmaceuticals Inc
US$ 0.1415
(31.26%)
489.28M
MGOLMGO Global Inc
US$ 0.7176
(-15.08%)
417.31M
SRMSRM Entertainment Inc
US$ 0.6999
(95.50%)
254.39M
INTCIntel Corporation
US$ 23.60
(-2.20%)
230.26M
NVDANVIDIA Corporation
US$ 138.85
(2.63%)
194.99M

VIR Discussion

View Posts
Monksdream Monksdream 2 months ago
VIR under $8
👍️0
DewDiligence DewDiligence 4 months ago
VIR reports 3Q24 results—9/30/24 cash=$1.19B:

https://www.businesswire.com/news/home/20241031806056/en
👍️0
Monksdream Monksdream 4 months ago
VIR under $10
👍️0
TheFinalCD TheFinalCD 7 months ago
https://x.com/NuntioBot/status/1819101232079786025

https://finviz.com/quote.ashx?t=VIR&p=d#google_vignette

Message in reply to:
VIR pares pipeline—reduces workforce 25%:

https://investors.vir.bio/news/news-details/2024/Vir-Biotechnology-Reports-Second-Quarter-2024-Financial-Results-and-Announces-Strategic-Restructuring-to-Prioritize-Clinical-Stage-Pipeline-Opportunities/default.aspx

VIR has terminated its programs in flu, COVID, and T cell-based viral vectors.

VIR also announced a collaboration with SNY to develop T-cell engagers (https://investors.vir.bio/news/news-details/2024/Vir-Biotechnology-Acts-on-Expanded-Strategy-of-Powering-the-Immune-System-Through-Exclusive-Worldwide-License-Agreement-with-Sanofi-for-Multiple-Potential-Best-in-Class-Clinical-Stage-T-cell-Engagers/default.aspx ), but financial terms of the collaboration were not disclosed.


2Q24 CC slides:
https://s203.q4cdn.com/628578897/files/doc_presentations/2024/Jul/Vir-Corporate-Presentation_Q2-2024.pdf
👍️0
DewDiligence DewDiligence 7 months ago
VIR pares pipeline—reduces workforce 25%:

https://investors.vir.bio/news/news-details/2024/Vir-Biotechnology-Reports-Second-Quarter-2024-Financial-Results-and-Announces-Strategic-Restructuring-to-Prioritize-Clinical-Stage-Pipeline-Opportunities/default.aspx

VIR has terminated its programs in flu, COVID, and T cell-based viral vectors.

VIR also announced a collaboration with SNY to develop T-cell engagers (https://investors.vir.bio/news/news-details/2024/Vir-Biotechnology-Acts-on-Expanded-Strategy-of-Powering-the-Immune-System-Through-Exclusive-Worldwide-License-Agreement-with-Sanofi-for-Multiple-Potential-Best-in-Class-Clinical-Stage-T-cell-Engagers/default.aspx ), but financial terms of the collaboration were not disclosed.


2Q24 CC slides:
https://s203.q4cdn.com/628578897/files/doc_presentations/2024/Jul/Vir-Corporate-Presentation_Q2-2024.pdf
👍️0
Monksdream Monksdream 7 months ago
VIR under $11
👍️0
Monksdream Monksdream 8 months ago
VIR under $10
👍️0
DewDiligence DewDiligence 8 months ago
VIR +18% on phase-2 HDV data at EASL:

https://finance.yahoo.com/news/tobevibart-monotherapy-combination-therapy-elebsiran-093000369.html

Note: HDV is a subset of HBV insofar as HDV resides within HBV’s capsid.
👍️0
DewDiligence DewDiligence 10 months ago
VIR 1Q24 CC transcript:

https://finance.yahoo.com/news/vir-biotechnology-inc-nasdaq-vir-170535096.html
👍️0
Monksdream Monksdream 10 months ago
VIR still reversing off the recent 52 week low
👍️0
DewDiligence DewDiligence 10 months ago
VIR reports 1Q24 results—3/31/24 cash=$1.51B(!):

https://www.businesswire.com/news/home/20240502260564/en

VIR re-iterated guidance for 2024 operating expenses of $650-680M.

CC slides:
https://investors.vir.bio/files/doc_financials/2024/q1/Vir-Corporate-Presentation_Q1-2024.pdf
👍️0
Monksdream Monksdream 10 months ago
VIR under $10
👍️0
DewDiligence DewDiligence 10 months ago
VIR adds two luminaries to BoD:

https://www.businesswire.com/news/home/20240418098064/en

The capsule bios in the PR speak for themselves.
👍️0
DewDiligence DewDiligence 12 months ago
VIR 4Q23 CC transcript:

https://finance.yahoo.com/news/q4-2023-vir-biotechnology-inc-185403667.html
👍️ 1
DewDiligence DewDiligence 12 months ago
VIR 4Q23 CC slides:

https://investors.vir.bio/files/doc_presentations/2024/02/22/Vir-Corporate-Presentation_Q4-2023.pdf
👍️0
DewDiligence DewDiligence 12 months ago
VIR reports 4Q23 results—issues 2024 expense guidance:

https://www.businesswire.com/news/home/20240222740501/en

12/31/23 cash was $1.63B, after burning $108M during 4Q23.

2024 guidance for SG&A + R&D GAAP expenses is $650-680M.

At the current share price, VIR has an enterprise value of roughly negative $200M.
👍️0
DewDiligence DewDiligence 12 months ago
VIR’s CMO left the company, which explains the exercise-and-hold transaction from January in the post I'm replying to:

https://finance.yahoo.com/news/vir-biotechnology-announces-dr-phil-213000676.html

Note: The above was issued on 2/20/24.
👍️0
DewDiligence DewDiligence 12 months ago
GSK, VIR terminate flu collaboration inked in 2021:

https://www.sec.gov/ixviewer/ix.html?doc=/Archives/edgar/data/0001706431/000162828024006346/vir-20240221.htm

This outcome is not surprising outcome insofar as the phase-2 trial of VIR-2484, the lead compound of the collaboration, was a failure ( #msg-172395320).
👍️0
DewDiligence DewDiligence 1 year ago
VIR’s CMO exercised and held ~$800K of stock yesterday:

https://www.sec.gov/Archives/edgar/data/1706431/000162828024000169/xslF345X05/wk-form4_1704311270.xml

The options in question did not expire until 2027-2028.
👍️0
DewDiligence DewDiligence 1 year ago
VIR cuts workforce 12%:

https://www.businesswire.com/news/home/20231213396441/en

It’s bizarre to see belt-tightening by a company with $1.7B of net cash (https://www.sec.gov/ix?doc=/Archives/edgar/data/0001706431/000162828023036702/vir-20230930.htm#i4ba948c416a6412b946073491455ca74_19 ), but it’s probably the right thing to do inasmuch as the stock’s EV is deeply negative.
👍️0
harry crumb harry crumb 1 year ago
Nice move today
👍️0
DewDiligence DewDiligence 2 years ago
VIR -45% on phase-2 failure in influenza:

https://finance.yahoo.com/news/vir-biotechnology-announces-topline-data-120000102.html Vir Biotechnology…today announced that the Phase 2 PENINSULA trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints. Why such a steep selloff? One reason is that VIR has tended to present itself to investors as all-powerful and all-knowing, which is perhaps a consequence of having George Scangos as (ex)CEO and having raised a huge amount of capital based on management’s reputation.
👍️0
DewDiligence DewDiligence 2 years ago
VIR starts 4-drug phase-2 HBV trial:

https://www.globenewswire.com/news-release/2023/05/11/2666740/0/en/Vir-Biotechnology-Announces-First-Patient-Dosed-in-New-Phase-2-Chronic-Hepatitis-B-Virus-Trial-Evaluating-Combinations-of-VIR-2218-VIR-3434-PEG-IFN%CE%B1-and-an-NRTI.html

The four drugs are: VIR-2218, a siRNA; VIR-3434, a mAb; PEG-IFN; and a (generic) nucleoside.

A separate phase-2 trial (VIR calls it a “subprotocol”) will test VIR-3434 and a nuke, with and without VIR-2218, in patients who are chronic inactive carriers of the HBV virus. I'm unclear as to whether this second trial is for research purposes or for an addressable commercial market.
👍️0
DewDiligence DewDiligence 2 years ago
48w VIR-2219 +peg-IFN—>31% HBs seroconverion:

https://www.globenewswire.com/news-release/2022/11/06/2549180/0/en/Vir-Biotechnology-Presents-New-Data-Evaluating-the-Potential-for-VIR-2218-and-VIR-3434-to-Achieve-a-Functional-Cure-for-Chronic-Hepatitis-B-Virus-HBV-Infection.html

The 31% figure is impressive insofar as peg-IFN by itself has a 48w seroconversion rate of only 5-10%. Of course, a 48w regimen of VIR-2219 + peg-IFN won’t be any easier to tolerate than 48w of peg-IFN monotherapy, so this regimen is still far from the ultimate answer for treating chronic HBV.

VIR has started testing the triple combination of VIR-2219 (siRNA) + VIR-3434 (mAb) + peg-IFN; initial data are expected in 2H23.
👍️0
DewDiligence DewDiligence 3 years ago
VIR EASL presentations:

https://www.globenewswire.com/news-release/2022/06/25/2469082/0/en/Vir-Biotechnology-Announces-New-Clinical-Data-From-its-Broad-Hepatitis-B-Program.html

No CC.
👍️0
DewDiligence DewDiligence 3 years ago
VIR HBV webcast slides:

https://investors.vir.bio/static-files/7ece44c3-0585-47af-81b4-2199889d6934
👍️0
DewDiligence DewDiligence 3 years ago
VIR -14% on amended Sotrovimab EUA due to Omicron BA.2 variant:

https://finance.yahoo.com/news/us-food-drug-administration-revises-200400156.html GlaxoSmithKline plc and Vir Biotechnology…today announced that the US Food and Drug Administration has amended the Emergency Use Authorization (EUA) Fact Sheet for sotrovimab, an investigational monoclonal antibody. The FDA has determined that, based on the totality of available evidence, including new live virus data generated by Vir, it is unlikely that the sotrovimab 500 mg dose will be effective against the Omicron BA.2 variant.

GSK and Vir are preparing a package of data in support of a higher dose of sotrovimab for the Omicron BA.2 subvariant and will be sharing these data with regulatory and health authorities around the world for discussion. This PR was issued after the close, but the market apparently got wind of the FDA decision about 3:45pm ET.
👍️0
DewDiligence DewDiligence 3 years ago
VIR 4Q21 results:

https://www.globenewswire.com/news-release/2022/02/24/2391890/0/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results.html As of December 31, 2021, excluding restricted cash, the Company had approximately $909.5 million in cash, cash equivalents, and investments. Excluding restricted cash and its equity investment in Brii Biosciences, the Company had approximately $766.4 million in cash, cash equivalents and investments.
👍️0
DewDiligence DewDiligence 3 years ago
VIR’s 2022 HBV newsflow:

https://www.globenewswire.com/news-release/2022/02/24/2391890/0/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-Fourth-Quarter-and-Full-Year-2021-Financial-Results.html In 2022, the Company expects data readouts from multiple trials evaluating VIR-2218 and VIR-3434:

• Initial data from the first cohorts of Phase 2 MARCH (Monoclonal Antibody siRNA Combination against Hepatitis B) trial of VIR-2218 in combination with VIR-3434, are expected in the first half of 2022.

• Additional data from the Phase 2 trial of VIR-2218 in combination with PEG-IFN-alpha are expected in the first half of 2022.

• Additional data from the Phase 1 monotherapy trial of VIR-3434 are expected in the first half of 2022.

• The Company’s collaborator, Brii Biosciences, continues to lead the Phase 2 trial evaluating VIR-2218 in combination with BRII-179, an investigational T cell vaccine, for the potential treatment of chronic HBV infection. Initial data are expected in the second half of 2022. Evidently, there will not be a 2022 readout from the phase-2 trial testing combinations of VIR-2218, GILD’s GS-9688, Vemlidy (TAF), and Opdivo (#msg-167061759, #msg-160854272, #msg-167063133).
👍️0
rwwest rwwest 3 years ago
Up so far on another Biotech down day
Seems like a good omen.
👍️0
DewDiligence DewDiligence 3 years ago
VIR slide set from JPM:

https://investors.vir.bio/static-files/7ecf45fb-6918-4cf8-9a02-b8c12183ca4f
👍️0
DewDiligence DewDiligence 3 years ago
VIR/GILD start phase-2 trial testing quadruple regimen of VIR-2218; GS-9688; Opdivo; and Vemlidy (TAF) in (both nuc-suppressed and viremic) HBV patients:

https://finance.yahoo.com/news/vir-biotechnology-announces-initiation-phase-133000267.html

I’m not sure why it took almost a year for this trial to begin enrolling patients—the PR announcing the collaboration was issued on 1/12/21.

Please see #msg-160854272 for background.
👍️0
HokieHead HokieHead 3 years ago
Loaded again. After omicron news all weekend this will be the next MRNA biotech. $75+ by years end for starters imo.
👍️0
HokieHead HokieHead 3 years ago
In $46, omicron play.
👍️0
DewDiligence DewDiligence 4 years ago
VIR starts HBV_combination_trial_of_ VIR-2218 and VIR-3434:

https://finance.yahoo.com/news/vir-biotechnology-initiates-phase-2-123000780.html The multi-center, open-label Phase 2 trial is designed to evaluate the safety, tolerability and efficacy of the combination of VIR-2218 and VIR-3434 in approximately 90 adult patients (ages 18 to 65) with chronic HBV infection receiving nucleot(s)ide reverse transcriptase inhibitor therapy. Both VIR-2218 and VIR-3434 will be administered via subcutaneous injection at varying dose levels over the course of the trial for a treatment period ranging from four to 20 weeks, and a follow-up period of up to 116 weeks, depending on the dosing cohort.

…VIR-2218 is an investigational small interfering ribonucleic acid (siRNA) designed to inhibit the production of all HBV proteins (X, polymerase, S and core), which may be acting as immune tolerogens. VIR-3434 is an investigational HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes, as well as reduce the level of virions and subviral particles in the blood. It has also been Fc engineered to include the XX2 “vaccinal mutation,” allowing it to potentially function as a therapeutic T cell vaccine against HBV. See #msg-164593550, #msg-161217289, and #msg-164599741 for related info.
👍️0
DewDiligence DewDiligence 4 years ago
VIR -6% on VIR-2218 and VIR-3434 monotherapy data presented at EASL:

https://finance.yahoo.com/news/vir-biotechnology-presents-clinical-data-125000851.html

CC to discuss these data with investment community at 11am ET.
👍️0
level42 level42 4 years ago
"profound efficacy." Vir Biotechnology and GSK plan to seek emergency use authorization for their experimental COVID-19 antibody therapy after interim data from a study showed 85% reduction in hospitalization and deaths among patients.


Based on these positive results, Vir and GlaxoSmithKline intend to request Emergency Use Authorization (EUA) for VIR-7831 from the U.S. Food and Drug Administration (FDA) and other international regulators.

"We are pleased that this unique monoclonal antibody was able to bring such a profound benefit to patients," GlaxoSmithKline chief scientific officer Dr. Hal Barron said. "We look forward to the possibility of making VIR-7831 available to patients as soon as possible."
👍️0
interloper interloper 4 years ago
Too high too fast. Very typical price movement. I you think your gonna ride a rocket to the moon you better be ready when the booster fuel runs out.
👍️0
dealerschool2006 dealerschool2006 4 years ago
why is VIR coming back down???
👍️0
rtrstock rtrstock 4 years ago
Huge disappointment.

This could go back to under 20.00 pps

Should have sold at 140.00

This stock price is just based on hype, the collapse is the reality of things.

👍️0
CatBirdSeat CatBirdSeat 4 years ago
Two New Rockships Taking Off After VIR

Behold! FNMA & FMCC

Ka Ching ! Baby! $$$$
👍️0
rtrstock rtrstock 4 years ago
I Should have sold at 140.00

Now it's in a death spiral.

Robinhood shows this listing at a completely different price than ihub.
👍️0
Srhogan1984 Srhogan1984 4 years ago
Full of crap haha
👍️0
ClayTrader ClayTrader 4 years ago
* * $VIR Video Chart 01-26-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
Srhogan1984 Srhogan1984 4 years ago
Sounds like a short to me. You need a bog squeeze? Haha
👍️0
DewDiligence DewDiligence 4 years ago
Today's move is somewhat scary in the context of #msg-160142077.
👍️0
DewDiligence DewDiligence 4 years ago
VIR—(+40% undeservedly, IMO)—on_interim_phase-1_data_for VIR-3434_in_HBV:

https://www.globenewswire.com/news-release/2021/01/26/2164220/0/en/Initial-Data-from-Ongoing-Phase-1-Trial-of-VIR-3434-for-Chronic-Hepatitis-B-Virus-Infection-Demonstrates-Significant-and-Rapid-Reduction-in-Hepatitis-B-Surface-Antigen.html

The mean reduction in HBsAg (n=6) was 1.3 logs after 8 days. That’s not bad, but neither is it a knock-your-socks-off result. Monotherapy is unlikely to generate a functional cure in HBV, no matter how potent the agent may be against HBsAg.

VIR-3434 is a monoclonal antibody and is VIR’s second HBV agent in the clinic; the first is VIR-2218, an RNAi agent (#msg-155042587).
👍️0
DewDiligence DewDiligence 4 years ago
Not really. It's just a phase-2 trial, not a full-fledged partnership.
👍️0
DewDiligence DewDiligence 4 years ago
GILD, VIR collaborate on phase-2 HBV trial:

https://www.businesswire.com/news/home/20210112005578/en The companies plan to initiate a Phase 2 trial evaluating combination therapy for both treatment-experienced and treatment-naïve people living with HBV. The multi-arm trial will evaluate different combinations of selgantolimod, Gilead’s investigational TLR-8 agonist; VIR-2218, Vir’s investigational small interfering ribonucleic acid (siRNA); and a commercially-sourced, marketed PD-1 antagonist. People in the trial with HBV treatment experience may also receive Gilead’s Vemlidy (tenofovir alafenamide fumarate, TAF). The primary outcome of the study will be the proportion of patients achieving a functional cure, defined as an off-therapy loss of hepatitis B surface antigen (HBsAg) and HBV DNA from the serum.

Both companies retain full rights to their individual product candidates and will discuss the potential path forward for any future combination studies based on the outcome of the Phase 2 trial. I.e., no cash is changing hands between the two companies.
👍️0
Srhogan1984 Srhogan1984 4 years ago
Huge news!
👍️0

Your Recent History

NASDAQ
VIR
Vir Biotechnology
FX
NPRGBP
NPR vs Sterling
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads